These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20414309)

  • 1. RNA interference: From tools to therapies.
    Baker M
    Nature; 2010 Apr; 464(7292):1225. PubMed ID: 20414309
    [No Abstract]   [Full Text] [Related]  

  • 2. RNA interference: Homing in on delivery.
    Baker M
    Nature; 2010 Apr; 464(7292):1225-8. PubMed ID: 20414308
    [No Abstract]   [Full Text] [Related]  

  • 3. siRNAs: their potential as therapeutic agents--Part II. Methods of delivery.
    Singh SK; Hajeri PB
    Drug Discov Today; 2009 Sep; 14(17-18):859-65. PubMed ID: 19540929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA interference: the silent treatment.
    Clayton J
    Nature; 2004 Sep; 431(7008):599-605. PubMed ID: 15457267
    [No Abstract]   [Full Text] [Related]  

  • 5. The road to therapeutic RNA interference (RNAi): Tackling the 800 pound siRNA delivery gorilla.
    Meade BR; Dowdy SF
    Discov Med; 2009 Dec; 8(43):253-6. PubMed ID: 20040280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Special delivery: targeted therapy with small RNAs.
    Peer D; Lieberman J
    Gene Ther; 2011 Dec; 18(12):1127-33. PubMed ID: 21490679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why RNAi makes sense.
    Hough SR; Wiederholt KA; Burrier AC; Woolf TM; Taylor MF
    Nat Biotechnol; 2003 Jul; 21(7):731-2. PubMed ID: 12833082
    [No Abstract]   [Full Text] [Related]  

  • 8. RNA interference as a gene knockdown technique.
    Shan G
    Int J Biochem Cell Biol; 2010 Aug; 42(8):1243-51. PubMed ID: 19442757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of RNA interference therapeutics using polycation-based nanoparticles.
    Howard KA
    Adv Drug Deliv Rev; 2009 Jul; 61(9):710-20. PubMed ID: 19356738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Future prospects of RNA interference in cancer therapies].
    Ashihara E
    Rinsho Ketsueki; 2009 Oct; 50(10):1577-88. PubMed ID: 19915369
    [No Abstract]   [Full Text] [Related]  

  • 12. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.
    Davis ME; Zuckerman JE; Choi CH; Seligson D; Tolcher A; Alabi CA; Yen Y; Heidel JD; Ribas A
    Nature; 2010 Apr; 464(7291):1067-70. PubMed ID: 20305636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecules in an RNAi world.
    Eggert US; Field CM; Mitchison TJ
    Mol Biosyst; 2006 Feb; 2(2):93-6. PubMed ID: 16880926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small RNAs: delivering the future.
    Blow N
    Nature; 2007 Dec; 450(7172):1117-20. PubMed ID: 18075597
    [No Abstract]   [Full Text] [Related]  

  • 16. siRNA delivery systems for cancer treatment.
    Oh YK; Park TG
    Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense and RNA interference approaches to target validation in pain research.
    Kurreck J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):179-87. PubMed ID: 15603251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of optimal sites for TGFB1 gene silencing by chitosan-TPP nanoparticle-mediated delivery of shRNA.
    Wang SL; Yao HH; Guo LL; Dong L; Li SG; Gu YP; Qin ZH
    Cancer Genet Cytogenet; 2009 Apr; 190(1):8-14. PubMed ID: 19264227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNAi Europe 2005.
    Berkhout B
    IDrugs; 2005 Dec; 8(12):978-81. PubMed ID: 16320127
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.